ESR2 and prostate carcinoma: In dissimilarity, ERβ, which manifestation declines by promoter DNA methylation as prostate cancer advancements, appears to play “anti-oncogenic role.” Certainly, estrogen receptor beta agonist has been reported to have averted the propagation of prostatic epithelium [91].